Pyruvate Dehydrogenase Complex Deficiency
Conditions
Keywords
Pyruvate Dehydrogenase Complex Deficiency
Brief summary
This is a medical research study to test a medication in patients with a disease called Pyruvate Dehydrogenase Complex (PDC) Deficiency. The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that triheptanoin may also be effective in the treatment PDC Deficiency. This study will investigate the safety and efficacy (how well it works) of triheptanoin in patients with PDC Deficiency.
Detailed description
Participation in the study will require the patient to participate in up to 10 visits over a two-year period. Five of those visits must be done at the UPMC Children's Hospital of Pittsburgh (CHP). Other visits can take place at CHP or remotely. All of these visits will include blood draws. Triheptanoin will be added to the patients' diet and administered at least 4 times per day. The target dose will be 1.2-3.9 g of triheptanoin per kg body weight with a max goal dose of about 4 g/kg per day. The triheptanoin will be provided to the patients at no cost. All other costs will be billed to the patients' insurance.
Interventions
DRUGTriheptanoin
Open-label design with doses of triheptanoin up to 4.0 gm/kg triheptanoin
Sponsors
Jirair Krikor Bedoyan
Ultragenyx Pharmaceutical Inc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
1. Age 1 year to \<18 years of age 2. Subjects with PDCD would need to have a metabolic physician following their clinical care needs prior to their enrollment in the study 3. Diagnosis of PDCD by molecular genetic confirmation of PDHA1, PDHB, DLAT, PDHX, or PDP1 mutation 4. Not pregnant or lactating 5. Parental permission and assent of minor and willingness to comply with study procedures 6. Not participating in any interventional treatment clinical trials 7. Not a recipient of gene therapy, organ transplant, or bone-marrow transplantation 8. If currently on any investigational drugs or therapies, must complete a 30-day washout period prior to Intake \& Dosing (Day 1). 9. Negative pregnancy test for all female patients of childbearing age. Individuals of childbearing potential must agree to use a highly effective method of contraception, and males must agree not to father a child or donate sperm. True abstinence for the duration of the study will also be accepted. 10. Subjects are following some form or type of ketogenic diet at the time of the screening visit.
Exclusion criteria
1. Diagnosis of medium-chain acyl-CoA dehydrogenase (MCAD) 2. Use of alcohol or drugs of abuse 3. Evidence of liver disease as defined by elevations of AST or ALT \>2x ULN in the past 6 months 4. Pregnant, breastfeeding, or lactating females 5. On any investigational product research study (and not completed the required 30-day washout period prior to Intake \& Dosing) or recipient of gene therapy or organ or bone-marrow transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants who report side-effects related to gastrointestinal (GI) distress | 24 months | — |
| Normalization of biochemical markers of disease (lactate) | 24 months | Change in lactate levels, comparing results from before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in mmol/L |
| Normalization of biochemical markers of disease (pyruvate) | 24 months | Change in pyruvate levels, comparing results from before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in mg/dl |
| Normalization of biochemical markers of disease (β-hydroxybutyrate level) | 24 months | Change in β-hydroxybutyrate levels, comparing results from before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in mmol/L |
| Normalization of biochemical markers of disease (Alanine/Leucine ratio) | 24 months | Change in Alanine/Leucine ratios, comparing results from before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in μmol/L |
| Normalization of biochemical markers of disease (Alanine/Lysine ratio) | 24 months | Change in Alanine/Lysine ratios, comparing results from before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in μmol/L |
| Normalization of biochemical markers of disease (Alanine/Proline ratio) | 24 months | Change in Alanine/Proline ratios, comparing results from before and after triheptanoin is initiated - this will be measured by the number of participants who experience any change; measured in μmol/L |
| More efficacious seizure control | 24 months | Measured by a reduction or alteration of home antiepileptics use, from before and after triheptanoin is initiated |
| More efficacious metabolic control | 24 months | Measured by a reduction in episodes of metabolic decompensation, from before and after triheptanoin is initiated |
| More efficacious disease control | 24 months | Measured by a reduction in the frequency of disease related hospitalizations, from before and after triheptanoin is initiated |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Improved quality of life | 24 months | Measured by a change in scores on the PedsQL, from before and after trihepatnoin is initiated |
| Improved long-term maintenance and tolerance of diet | 24 months | Measured by parental report of diet maintenance and tolerance, from before and after triheptanoin is initiated |
Countries
United States
Contacts
CONTACTAngela Riemenschneider
CONTACTJirair Bedoyan, MD, PhD
PRINCIPAL_INVESTIGATORJirair Bedoyan, MD, PhD
UPMC Children's Hospital of Pittsburgh
Outcome results
None listed